DSM appoints new Chief Technology Officer
(Thomson Reuters ONE) -
Royal DSM, the global Life Sciences and Materials Sciences company, today
announces the following:
Marcel Wubbolts, currently Vice President R&D DSM Innovation Center, will assume
the position of Chief Technology Officer for DSM as of October 1, reporting to
Rob van Leen, Chief Innovation Officer.
Marcel holds a PhD from the University of Groningen, NL, was post-doc and
Assistent Professor at the ETH in Zürich. He joined DSM as a senior scientist
and became Managing Director of DSM Biotech GmbH, in Jülich, Germany.
Thereafter, he was Competence Manager Biocatalysis & Biotransformations and then
became Program Director at the DSM Innovation Center in Delft, the Netherlands,
running the Industrial (White) Biotechnology program. Since January 2011 he is
at his current position.
Marcel has published over 80 publications and patents in the area of
biocatalysis and metabolic engineering. He serves on the board of the WG Applied
Biocatalysis of the Dutch Society for Biotechnology (NBV); the board of the
European Federation of Biotechnology Section on Applied Biocatalysis (ESAB); the
Industrial Biotechnology council of EuropaBio; the supervisory board of ERA-NET
Industrial Biotechnology and leads the Industrial Biotechnology Section of
Suschem, European Technology Platform for Sustainable Chemistry.
Marcel will succeed Jos Put who will continue to be an advisor to DSM e.g. in
the field of material sciences and for several of the DSM Science and Technology
awards.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM's
22,000 employees deliver annual net sales of about ? 9 billion. The company is
listed on NYSE Euronext. More information can be found at www.dsm.com
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 10 4590275
e-mail media.relations(at)dsm.com e-mail investor.relations(at)dsm.com
Picture-jpg:
http://hugin.info/130663/R/1524197/460061.jpg
Press release-pdf:
http://hugin.info/130663/R/1524197/460060.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
[HUG#1524197]
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2011 - 10:15 Uhr
Sprache: Deutsch
News-ID 55648
Anzahl Zeichen: 3718
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM appoints new Chief Technology Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
